FDA approves Satsuma’s migraine nasal spray after rejection in 2024news2025-05-01T14:55:41+00:00May 1st, 2025|Endpoints News|
Biogen Q1 earnings: Leqembi sales improving slowly following lackluster launchnews2025-05-01T11:35:28+00:00May 1st, 2025|Endpoints News|
Lilly meets sales expectations, but Novo gains on PBM winnews2025-05-01T11:23:03+00:00May 1st, 2025|Endpoints News|
Amicus grabs Dimerix’s rare kidney disease drug for $30M upfrontnews2025-05-01T10:34:56+00:00May 1st, 2025|Endpoints News|
Moderna Q1 earnings: Company expands effort to control spending in ‘uncertain environment’news2025-05-01T10:30:47+00:00May 1st, 2025|Endpoints News|
BeiGene gets key win in patent spat over Brukinsanews2025-04-30T19:42:52+00:00April 30th, 2025|Endpoints News|
Regeneron loses bid to fend off false claims fight over Eyleanews2025-04-30T17:41:33+00:00April 30th, 2025|Endpoints News|
FDA approves Johnson & Johnson’s rare disease drug that’s expected to compete with argenx and UCBnews2025-04-30T13:22:14+00:00April 30th, 2025|Endpoints News|
Updated: Novartis to buy Regulus Therapeutics for up to $1.7Bnews2025-04-30T11:37:06+00:00April 30th, 2025|Endpoints News|
GSK’s supply chain ‘reset’ after Haleon spinoff to ease tariff impact, CEO saysnews2025-04-30T11:17:19+00:00April 30th, 2025|Endpoints News|
